Skip to main content

Table 2 Characteristics of included studies in meta-analysis

From: Role of lymph node dissection in the management of upper tract urothelial carcinomas: a meta-analysis

Study

Type of study

Gender

Patients (n)

Follow-up median (month)

Median age (year)

Node status (overall)/ LND or NLND

Extent of LND

Tumor location

Pathologic tumor stage

Tumor grade

Outcome

Kondo T et al 2014 [31]

Prospective

Male 112

Female 54

166

23.7

72.4

pN0 69 pNx 86 pN+  11

Renal pelvis tumor: LN from the renal hilar to the inferior mesenteric artery.

Tumor of upper 2/3 ureter: LN from the renal hilar to the aortic bifurcation.

Tumor of lower 1/3 ureter: the ipsilateral pelvic LN

Renal pelvis 90

Ureter 76

≤pT1 62

pT2 27

pT3 72

pT4 5

Low 71

High 95

CSS

Ouzzane A et al 2013 [16]

Retrospective

Male 484

Female 228

714

27.0

70.0

pN0 204 pNx 460 pN+  50

NA

Renal pelvis 388

Pelvis+ureter 90

Multifocal 236

pTa/Tis 209

pT1 168

pT2 74

pT3 224

pT4 39

G1 71

G2 244

G3 399

CSS, RFS

Mason RJ et al. 2012 [15]

Retrospective

Male 654

Female 375

1029

19.8

68.6

pN0 199 pNx 753 pN+  77

NA

Renal pelvis 538

Pelvis+ureter 213

Ureter 250

pTa/Tis 108

pT1 463

pT2 160

pT3 244

pT4 54

Low 340

High 689

CSS, RFS

Burger M et al 2011 [30]

Retrospective

Male 542

Female 243

785

34.0

68.0

pN0 136 pNx 595 pN+  54

Hilar & regional LN adjacent to ipsilateral great vessel

NA

pTa 165

pTis 10

pT1 196

pT2 148

pT3 222

pT4 44

G1 100

G2 226

G3 459

CSS, RFS

Abe T et al 2010 [29]

Retrospective

Male 195

Female 98

293

NA

69.2

pN0 130 pNx 141 pN+  22

Tumor of renal pelvis tumor & upper 2/3 ureter: Hilar & regional LN adjacent to ipsilateral great vessel

Lower ureteral tumor: ipsilateral pelvic LN

Renal pelvis 157

Pelvis+ureter 24

Ureter 112

pTa/Tis 53

pT1 66

pT2 56

pT3 101

pT4 17

Low 185

High 108

RFS

Lughezzani et al 2010 [14]

Retrospective

Male 1666

Female 1158

2824

43.0

72.0

pN0 1835 pNx 747 pN+  242

NA

Renal pelvis 1913

Ureter 911

pT1 867

pT2 500

pT3 584

pT4 873

G1 156

G2 935

G3 1234

G4 499

CSS

Roscigno M et al 2009 [28]

Retrospective

NA

1130

45.0

69.1

pN0 412 pNx 578 pN+  140

Renal pelvis and proximally ureteral tumor: LN from the renal hilar to the inferior mesenteric artery

Mid and lower ureteral tumors:

LN from the renal hilar to the bifurcation of the common iliac artery and ipsilateral pelvic LN

NA

pT1 317

pT2 269

pT3–4544

Low 291

High 839

CSS

Kondo T et al. 2007 [27]

Retrospective

Male 113

Female 56

169

37.3

67.5

LND 81 NLND 88

Renal pelvis tumor: LN from the renal hilar to the inferior mesenteric artery

Tumor of upper 2/3 ureter: LN from the renal hilar to the aortic bifurcation

Tumor of lower 1/3 ureter: ipsilateral pelvic LN

Renal pelvis 100

Upper ureter 9

Midureter 20

Lower ureter 40

≤pT1 45

pT2 34

pT3 79

pT4 9

NA

CSS

Secin FP et al. 2007 [26]

Retrospective

Male 166

Female 86

252

37.2

69.0

pN0 105 pNx 119 pN+  28

NA

NA

pTa 71

pTis 12

pT1 46

pT2 35

pT3 72

pT4 8

G1 64

G2 38

G3 143

CSS

Brausi MA et al 2007 [25]

Retrospective

Male 59

Female 23

82

64.7

LND 67.8

NLND 67.1

LND 40 NLND 42

Renal pelvis and upper ureteral tumor: LN from the renal hilar to the inferior mesenteric artery

Mid ureteral tumors: LN from the renal hilar to the bifurcation of the common iliac artery

Lower ureteral tumor: ipsilateral pelvic LN

Renal pelvis 47

Pelvis+ureter 7

Ureter 28

pT2 38

pT3 36

pT4 8

G2 44

G3 38

CSS

Miyake H et al.. 1998 [24]

Retrospective

Male 53

Female 19

72

49

LND 64

NLND 67

LND 35 NLND 38

Renal pelvis and upper ureteral tumor: LN from the renal hilar to the inferior mesenteric artery

Mid ureteral tumor: LN from the renal hilar to the bifurcation of the common iliac artery

Lower ureteral tumor: ipsilateral pelvic LN

Renal pelvis 40

Pelvis+ureter 3

Ureter 29

pTa 11

pT1 25

pT2 18

pT3 14

pT4 4

G1 12

G2 33

G3 37

CSS

  1. LND Lymph node dissection, NLND Non-LND, NA Not available, pN+ Positive lymph node, pN0 Negative lymph node, pNx Not undergo lymph node dissection, CSS cancer-specific survival, RFS recurrence-free survival